These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 17391996

  • 1. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.
    Zimran A, Loveday K, Fratazzi C, Elstein D.
    Blood Cells Mol Dis; 2007; 39(1):115-8. PubMed ID: 17391996
    [Abstract] [Full Text] [Related]

  • 2. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK, Cheng G, Tang J, Song J, Peng WX.
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL, Stalker D, Keirns J.
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [Abstract] [Full Text] [Related]

  • 6. [Diagnosis and therapy of Gaucher disease].
    Ehlen C, Heintges T, Niederau C.
    Med Klin (Munich); 1995 May 15; 90(5):284-90. PubMed ID: 7791695
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study.
    Burge DJ, Bookbinder SA, Kivitz AJ, Fleischmann RM, Shu C, Bannink J.
    Clin Ther; 2008 Oct 15; 30(10):1806-16. PubMed ID: 19014836
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB, Dowell JA, Pratt RD.
    Clin Ther; 2007 Jul 15; 29(7):1368-80. PubMed ID: 17825688
    [Abstract] [Full Text] [Related]

  • 9. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.
    Wong SL, Barriere SL, Kitt MM, Goldberg MR.
    J Antimicrob Chemother; 2008 Oct 15; 62(4):780-3. PubMed ID: 18586659
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A.
    Pharmacotherapy; 2007 Oct 15; 27(10):1353-60. PubMed ID: 17896890
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 15; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 12. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K.
    Clin Ther; 2007 Apr 15; 29(4):617-25. PubMed ID: 17617285
    [Abstract] [Full Text] [Related]

  • 13. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 15; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 14. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A, Down G, Newland A, Reynard K, Rousell V, Salmon E, Scott R.
    Clin Ther; 2007 Jul 15; 29(7):1415-20. PubMed ID: 17825692
    [Abstract] [Full Text] [Related]

  • 15. Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes.
    Murray GJ, Oliver KL, Jin FS, Brady RO.
    J Cell Biochem; 1995 Feb 15; 57(2):208-17. PubMed ID: 7759558
    [Abstract] [Full Text] [Related]

  • 16. [Enzyme replacement therapy in type 1 Gaucher's disease].
    Aggio MC, Fernández V, Marcilese M.
    Medicina (B Aires); 1994 Feb 15; 54(2):140-4. PubMed ID: 7997130
    [Abstract] [Full Text] [Related]

  • 17. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F, Sieverts H, Benz-Bohm G, Landwehr P, Harzer K.
    Monatsschr Kinderheilkd; 1992 Oct 15; 140(10):740-4. PubMed ID: 1331780
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R, Park G, Damle B, Chertkoff R, Alon S.
    PLoS One; 2015 Oct 15; 10(6):e0128986. PubMed ID: 26053270
    [Abstract] [Full Text] [Related]

  • 19. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
    Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM.
    Expert Opin Pharmacother; 2009 Nov 15; 10(16):2641-52. PubMed ID: 19743939
    [Abstract] [Full Text] [Related]

  • 20. The pharmacokinetics and pharmacodynamics of alfaxalone in cats after single and multiple intravenous administration of Alfaxan at clinical and supraclinical doses.
    Whittem T, Pasloske KS, Heit MC, Ranasinghe MG.
    J Vet Pharmacol Ther; 2008 Dec 15; 31(6):571-9. PubMed ID: 19000281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.